Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2002

View Archived Issues

Medtronic acquires Endonetics

Ibuprofen blocks beneficial effects of aspirin in heart attack prevention

Osteopontin may offer a potential target in blocking development of progressive multiple sclerosis

Defining the mechanism by which niacin mediates its antiatherogenic properties

Meta-analysis shows efficacy of terazosin is independent of prostate size

Tamsulosin may provide effective treatment for reboxetine-associated urinary hesitancy

Roche claims new antiinflammatory and analgesic compounds

Avax Technologies buys back interest in Australian joint venture

New compounds for the treatment of asthma in the Roche pipeline

Warner-Lambert describes a new method for inhibiting amyloid protein aggregation

Nippon Shinyaku patents novel nociceptin receptor agonists

Eisai reports new acetylcholinesterase inhibitors

Amino acid derivatives and their use as medicines described by SCRAS researchers

Antiviral drugs containing nitrogenous compounds disclosed by Kureha

Merck/Schering-Plough seeks FDA approval for Zetia in elevated cholesterol

Ilex buys out Millennium's equity interests in their Campath joint venture

Therion Biologics' cancer vaccine enters phase I trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...